ArticleInternational journal of medical microbiology : IJMM2014
In vitro and in vivo cell invasion and systemic spreading of Mycoplasma agalactiae in the sheep infection model.
Article in International journal of medical microbiology : IJMM, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- Capsular polysaccharide of Mycoplasma mycoides subsp. capri contributes to phenotypic diversity promoting distinctive immune responses.PLoS pathogens · 2025Article
- Ben_0691 functions as an IRG-47 mycoplasma stimulator that mediates host cell resistance to Mycoplasma mycoides subsp. mycoides infection.Communications biology · 2025Article
- Virulence Is More than Adhesion and Invasion Ability, an In Vitro Cell Infection Assay of BovineMicroorganisms · 2025Article
- Article
- Review
- Unveiling the stealthy tactics: mycoplasma's immune evasion strategies.Frontiers in cellular and infection microbiology · 2023Review
- High Concentration of FBS Can Save mTOR Down-Regulation Caused byVeterinary sciences · 2022Article
- Serum Resistance ofPathogens (Basel, Switzerland) · 2022Article
- Sheep Infection Trials with 'Phase-Locked' Vpma Expression Variants ofMicroorganisms · 2022Article
- Predominant Single Stable VpmaV Expression in Strain GM139 and Major Differences withAnimals : an open access journal from MDPI · 2022Article
- Annexin A2 regulatesFrontiers in immunology · 2022Article
- Characterization of the interactome profiling ofFrontiers in microbiology · 2022Article
- Analysis of DnaK Expression from a Strain ofInternational journal of molecular sciences · 2021Article
- Nicotinamide Adenine Dinucleotide-Dependent Flavin Oxidoreductase ofFrontiers in microbiology · 2021Article
- Paracellular Pathway-Mediated Mycoplasma hyopneumoniae Migration across Porcine Airway Epithelial Barrier under Air-Liquid Interface Conditions.Infection and immunity · 2020Article
- Are alternative antibiotics needed for antibiotic-nonresponsive Mycoplasma pneumoniae pneumonia?Clinical and experimental pediatrics · 2020Article
- Early Corticosteroid Therapy forJournal of clinical medicine · 2019Article
- Subversion of the Immune Response by Human Pathogenic Mycoplasmas.Frontiers in microbiology · 2019Review
- A Presumed Etiology of Kawasaki Disease Based on Epidemiological Comparison With Infectious or Immune-Mediated Diseases.Frontiers in pediatrics · 2019Article
- Antimicrobial Resistance inMicrobiology spectrum · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Generally regarded as extracellular pathogens, molecular mechanisms of mycoplasma persistence, chronicity and disease spread are largely unknown. Mycoplasma agalactiae, an economically important pathogen of small ruminants, causes chronic infections that are difficult to eradicate. Animals continue to shed the agent for several months and even years after the initial infection, in spite of long antibiotic treatment. However, little is known about the strategies that M. agalactiae employs to survive and spread within an immunocompetent host to cause chronic disease. Here, we demonstrate for the first time its ability to invade cultured human (HeLa) and ruminant (BEND and BLF) host cells. Presence of intracellular mycoplasmas is clearly substantiated using differential immunofluorescence technique and quantitative gentamicin invasion assays. Internalized M. agalactiae could survive and exit the cells in a viable state to repopulate the extracellular environment after complete removal of extracellular bacteria with gentamicin. Furthermore, an experimental sheep intramammary infection was carried out to evaluate its systemic spread to organs and host niches distant from the site of initial infection. Positive results obtained via PCR, culture and immunohistochemistry, especially the latter depicting the presence of M. agalactiae in the cytoplasm of mammary duct epithelium and macrophages, clearly provide the first formal proof of M. agalactiae's capability to translocate across the mammary epithelium and systemically disseminate to distant inner organs. Altogether, the findings of these in vitro and in vivo studies indicate that M. agalactiae is capable of entering host cells and this might be the strategy that it employs at a population level to ward off the host immune response and antibiotic action, and to disseminate to new and safer niches to later egress and once again proliferate upon the return of favorable conditions to cause persistent chronic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.